| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
18,798 |
14,084 |
$2.19M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
17,351 |
13,819 |
$2.11M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
7,667 |
6,534 |
$1.12M |
| 71045 |
Radiologic examination, chest; single view |
8,133 |
4,120 |
$550K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,393 |
4,386 |
$297K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,177 |
1,877 |
$183K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,939 |
2,465 |
$167K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,538 |
2,082 |
$162K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
31,697 |
22,507 |
$159K |
| 80053 |
Comprehensive metabolic panel |
22,219 |
16,317 |
$158K |
| 36415 |
Collection of venous blood by venipuncture |
49,807 |
34,944 |
$129K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
335 |
79 |
$120K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,529 |
1,657 |
$118K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
2,658 |
2,179 |
$105K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,625 |
1,172 |
$88K |
| 64493 |
|
81 |
60 |
$61K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,318 |
1,132 |
$45K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,213 |
669 |
$37K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
383 |
72 |
$29K |
| 84484 |
|
4,497 |
2,956 |
$28K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,200 |
2,700 |
$28K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
922 |
766 |
$27K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
169 |
102 |
$21K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
6,427 |
4,785 |
$18K |
| 81001 |
|
7,487 |
5,863 |
$18K |
| 70450 |
Computed tomography, head or brain; without contrast material |
272 |
145 |
$17K |
| 80061 |
Lipid panel |
2,169 |
1,797 |
$16K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
595 |
523 |
$14K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
344 |
287 |
$14K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
817 |
734 |
$14K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,760 |
2,307 |
$13K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
42 |
26 |
$12K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
235 |
121 |
$12K |
| 71046 |
Radiologic examination, chest; 2 views |
136 |
110 |
$11K |
| 87634 |
|
177 |
139 |
$9K |
| 94760 |
|
79 |
73 |
$8K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
902 |
728 |
$8K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
200 |
187 |
$6K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
200 |
187 |
$6K |
| 83690 |
|
1,293 |
1,028 |
$5K |
| 73630 |
|
167 |
91 |
$4K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
28 |
24 |
$4K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
22 |
20 |
$3K |
| 92567 |
|
86 |
66 |
$3K |
| 97597 |
|
49 |
12 |
$3K |
| 80076 |
|
568 |
461 |
$3K |
| 87481 |
|
41 |
41 |
$3K |
| 85730 |
|
577 |
386 |
$3K |
| 83721 |
|
1,088 |
873 |
$3K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
59 |
53 |
$2K |
| 85610 |
|
739 |
474 |
$2K |
| 83605 |
|
470 |
302 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
30 |
25 |
$2K |
| 82728 |
|
391 |
330 |
$2K |
| 83735 |
|
804 |
617 |
$2K |
| 82550 |
|
1,002 |
687 |
$2K |
| 71250 |
|
30 |
12 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
12 |
12 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
395 |
330 |
$1K |
| 82553 |
|
896 |
613 |
$1K |
| 83550 |
|
390 |
334 |
$1K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
41 |
41 |
$1K |
| 83880 |
|
108 |
78 |
$1K |
| 83540 |
|
411 |
352 |
$1K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
56 |
25 |
$990.52 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
92 |
57 |
$842.89 |
| 84439 |
|
126 |
110 |
$736.68 |
| 87510 |
|
41 |
41 |
$726.23 |
| 82607 |
|
138 |
111 |
$683.02 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
43 |
38 |
$667.80 |
| 81025 |
|
120 |
92 |
$643.64 |
| 94010 |
|
12 |
12 |
$605.36 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
259 |
180 |
$591.74 |
| 99215 |
Prolong outpt/office vis |
16 |
12 |
$531.35 |
| 82746 |
|
126 |
98 |
$514.44 |
| 82150 |
|
164 |
138 |
$486.91 |
| 84703 |
|
84 |
77 |
$463.18 |
| 85379 |
|
37 |
28 |
$289.04 |
| 99443 |
|
52 |
27 |
$288.94 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
13 |
12 |
$240.80 |
| 82043 |
|
74 |
62 |
$211.88 |
| 86803 |
|
13 |
12 |
$142.70 |
| Q3014 |
Telehealth originating site facility fee |
33 |
31 |
$133.46 |
| 81003 |
|
142 |
110 |
$96.85 |
| 82570 |
|
33 |
24 |
$67.34 |
| 85027 |
|
12 |
12 |
$51.76 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
321 |
251 |
$17.86 |
| A0425 |
Ground mileage, per statute mile |
2,755 |
1,537 |
$0.00 |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
121 |
68 |
$0.00 |
| 91300 |
|
21 |
19 |
$0.00 |
| 90662 |
|
18 |
16 |
$0.00 |
| 3078F |
|
18 |
15 |
$0.00 |
| 11721 |
|
28 |
13 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
19 |
16 |
$0.00 |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
1,138 |
679 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
32 |
27 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
93 |
65 |
$0.00 |
| 0001A |
|
23 |
20 |
$0.00 |
| 3074F |
|
16 |
13 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
13 |
12 |
$0.00 |